Background. Although the University of Wisconsin (U.W.) solution continues to be the most commonly used for intra-abdominal organs, a new solution, Celsior, already used for heart and lungs, has been proposed for kidney and liver preservation. The aim of this research was to assess the effect of Celsior as compared with U.W. on immediate graft function and a 2-year follow-up of kidney transplants.
INTRODUCTION
Simple cold storage is the most widely used technique in Europe for the preservation of cadaveric kidneys for transplantation (1) . The aim of preservation is to maintain the donor kidney in an optimal state, morphologically and biochemically, from time of harvesting to transplantation. The improvement of preservation should include the extension of ischemic tolerance during anaerobiosis and limitation of cell damage during reperfusion. The proof of the efficacy of a preservation solution is the functioning of the kidney allograft after an ischemic period (2) .
The introduction of the University of Wisconsin (U.W.) solution in 1987 had a major influence on solid-organ transplantation by extending safe preservation times for kidneys up to 72 hr (3) . Although the U.W. solution remains the most widely used for intra-abdominal organs (4), a new solution, Celsior, has been proposed for kidney and liver preservation (5, 6) . Celsior is successfully used as a universal cold storage solution for all intrathoracic organs (7, 8) . Therefore, by using this solution in a multiple-organ donor, it might be possible to perform an in situ vascular flush with a single cold storage solution.
Regarding composition, U.W. solution contains lactobionate, raffinose, and hydroxyethyl starch as osmotic components, mixed with a phosphate buffer and a high potassium content as well as small amounts of the antioxidant glutathione, adenosine as a nucleotide precursor, the free-radical scavenger allopurinol, dexamethasone, insulin, and penicillin (1) . Celsior solution is a slightly hypertonic low-viscosity solution with a low potassium content. It is also characterized by a high buffering capacity and contains ketoglutarate as an energy substrate (7) .
In September 1998, a multicenter trial was started to determine the efficacy of the Celsior solution in the clinical preservation of the kidney. This study was carried out in cooperation with the University of Parma, the University of Modena, and the University of Pisa, and was designed as a prospectively randomized study. This report contains data collected as of September 2000.
MATERIALS AND METHODS

Study design.
A prospective, randomized, open clinical trial was instituted to evaluate the kidney preservation properties of U.W. and Celsior solutions in clinical transplantation; four Italian transplantation centers of the AIRT organization (Associazione InterRegionale Trapianti/Interregional Transplantation Association) were enrolled in this multicenter trial (University of Bologna, University of Parma, University of Modena, and University of Pisa).
Study protocol. Standardized explantation, storage, and transplantation procedures were used. Organs were always harvested by the same surgical team in a randomized fashion. Only first transplantations were included, and all donors and recipients were older than 15 years old. Kidneys allografts were perfused with standard volumes according to donor weight; we used an aortic perfusion of 60 ml/kg with Celsior solution and an aortic perfusion of 30 ml/kg with U.W. solution; perfusate height was always 80 to 100 cm, and the flushing time was almost the same in both groups. At the end of the perfusion period, renal grafts were immediately excised, transferred to a cold environment surrounded by ice, and bench perfused with 500 ml of the same solution for each kidney. Celsior (Sangstat Medical, Menlo Park, CA) and U.W. (Viaspan, Du Pont Merck Pharmaceutical, Wilmington, DE) compositions are reported in Table 1 .
A comprehensive protocol and data collection system established to compare donor procedures and pre-and postoperative data on kidney recipients. Donor information includes donor condition, donor management and operation for harvesting and preservation of organs, and preservation times. Recipient information includes preand perioperative status, recipient management, implantation procedure, short-term posttransplantation follow-up until the patient was discharged, and a 2-year follow-up.
Kidney functions were monitored daily until the day of discharge. Renal function outcome was compared by evaluating delayed graft function (DGF) rates, daily urinary output, the evolution of the mean serum creatinine at 1, 3, 5, 7, and 15 days until the day of discharge and the posttransplantation dialysis rate. DGF of the transplanted kidney was defined as the absence of life-sustaining renal function requiring one or more dialysis sessions within the first days after transplantation.
Study population. As of September 2000, 100 multiple-organ donors were included in the study. This resulted in 187 renal transplants. Thirteen kidneys were not transplanted (six in the U.W. group and seven in the Celsior group) because they were harvested from marginal donors and rejected based on the histological examination performed by the same pathologist. In particular, grafts were excluded when histological examination showed massive glomerular sclerosis, tubular atrophy, interstitial fibrosis, and arteriolar narrowing. Ninety-nine kidneys were harvested and preserved in Celsior solution and 88 in U.W. solution.
Immunosuppression. Recipients were maintained on standard immunosuppressive therapy, which included either tacrolimus or cyclosporine; 58.8% of the patients with a Celsior kidney received cyclosporine as the basic immunosuppressive therapy; the remaining 41.2% of the patients received tacrolimus as the basic immunosuppression. For the U.W. preserved kidneys, these figures were 63.2% and 36.8%, respectively.
Statistical analysis. Univariate analyses employed the MannWhitney U test and chi-square tests to assess the differences between the study groups. Graft survival was calculated with KaplanMeier analysis. P values Ͻ0.05 were regarded as statistically significant.
RESULTS
The groups were comparable with regard to donor characteristics: age, cause of death, duration of intensive care, systolic pressure, dopamine, number of hypotension episodes, serum creatinine, urea, and urinary output per hour ( Table  2 ). The groups were also comparable in relevant recipient characteristics, such as age, mean number of HLA A/B/DR mismatches, maximum level of panel-reactive antibodies, and warm and cold ischemia times (Table 3) .
Three immediate graft failures were observed in the Celsior group and one in the U.W. group; all graft failures were confirmed to be of surgical and immunological origin and not preservation related. There was no postoperative mortality in either group. For rejection, 12.1% of the patients in the Celsior group and 13.1% of the patients in U.W. group showed rejection before they were discharged (Pϭn.s.).
Although the incidence of DGF was higher in U.W. transplants (33.9%) compared with Celsior transplants (31.3%), it was not statistically significant. Consequently, the mean overall dialysis after transplantation rate was 1.9 for recipients with U.W. preserved kidneys versus 1.0 for the patients with Celsior kidneys (Pϭn.s.). Figure 1 illustrates the evolution of mean serum creatinine during the postoperative period until the day of discharge; comparison of these data showed a lower mean level for Celsior-protected kidneys compared with U.W. protected kidneys but the difference was not statistically significant.
The mean posttransplantation daily urinary output in the U.W. group tended to be lower than in the Celsior group, but was also not statistically significant (Fig. 2) .
The 2-year graft survival rate in kidneys preserved with Celsior was 84% compared with 75% for U.W.-preserved kidneys, with no statistical significance (Fig. 3) .
In the analysis of subgroups with cold ischemia times longer than 17 hr (41 grafts in the U.W. group and 45 grafts in the Celsior group), there was no statistical difference in DGF (43.9% in U.W. kidneys vs. 40% in Celsior kidneys), mean overall posttransplantation dialysis rate (3.9 in U.W. grafts vs. 2.9 in Celsior grafts), evolution of mean serum creatinine (7.08Ϯ2.4 mg/dL vs. 6.2Ϯ2.1 mg/dL at postoperative day 1; 6.2Ϯ3.3 mg/dL vs. 5.1Ϯ3.4 mg/dL at postoperative day 3; 5.3Ϯ3.4 mg/dL vs. 4.6Ϯ3.3 mg/dL at postoperative day 5; 4.7Ϯ3.4 mg/dL vs. 4.2Ϯ3.3 mg/dL at postoperative day 7; 3.2Ϯ2.2 mg/dL vs. 2.7Ϯ2.02 at postoperative day 15, 2.2Ϯ1.5 mg/dL vs. 1.9Ϯ1.08 mg/dL at the day of discharge, in the U.W. and Celsior groups, respectively) and daily urinary output (1567.7Ϯ1549.1 ml vs. 2264.8Ϯ2575.1 ml at postoperative day 1; 1621.9Ϯ1477.1 ml vs. 1633.09Ϯ1471.6 ml at postoperative day 3; 1626.9Ϯ1670.5 ml vs. 1730.4Ϯ1138.4 ml at postoperative day 5; 1651.1Ϯ1228.2 ml vs. 1823.5Ϯ1174.4 ml at postoperative day 7; 1731.2Ϯ1121.1 ml vs. 1924.3Ϯ1235.6 ml at postoperative day 15; 1753.5Ϯ1152.8 ml vs. 1970.6Ϯ1210.4 ml at the day of discharge, in the U.W. and Celsior groups, respectively).
DISCUSSION
Optimal use of scarce resources in cadaveric renal transplantation requires optimal kidney preservation. Good preservation should keep the incidence of DGF as low as possible (1). Because DGF is detrimental for the patient, optimal 
preservation of the allograft plays a fundamental role in clinical renal transplantation (9) . U.W. solution was a milestone in organ preservation. It introduced three fundamental philosophies: first, osmotic concentration was not maintained by metabolically active glucose but achieved by the administration of metabolically inert substrates like lactobionate and raffinose; second, the additional administration of colloid carrier hydroxyethylstarch was important; third, the oxygen free-radical scavengers, glutathione, allopurinol, and adenosine were added (10) .
Kidney preservation with U.W. was tested prospectively in a Multicenter European Trial and was superior to EuroCollins because it decreased the rate of DGF (11) . Therefore, at present, U.W. solution is regarded as the standard preservation solution for intra-abdominal organs and is the most widely used solution.
Although Celsior solution was initially developed for heart and lung preservation, it soon became apparent that its use could be extended to other organs. The formulation of this new preservation solution addresses the prevention of cell swelling by using mannitol and lactobionate, the prevention of oxygen-derived free-radical injury by using reduced glutathione, histidine, and mannitol, and the enhancement of energy production by using glutamate (12) .
In Celsior solution, impermeant inert osmotic carrier characteristics from U.W. solution using lactobionate and mannitol and the strong buffer philosophy from the HTK solution using histidine buffer are mixed. Celsior solution also contains more oxygen free-radical scavengers, and in terms of electrolytes, is a high sodium, low potassium solution, which is unique (10) .
There is agreement that the reduced glutathione present in Celsior is one of the most effective antioxidants currently available for clinical use, in contrast to shelf-stored U.W., where glutathione is rapidly oxidized. Moreover, Celsior, in contrast to U.W., is devoid of colloids, which results in a dramatic decrease in its viscosity (Celsior, 1.150 mm 2 /sec; U.W., 3.159 mm 2 /sec) and a related improvement in its per- fusability characteristics. For this reason, in our protocol the aortic perfusion was twice the volume in the Celsior group compared with the U.W. group. Although the volume of perfusion differed, the anticipated cooling effect on the kidneys was only slightly different because grafts at the end of the perfusion period were immediately excised and transferred to a cold environment.
There are concerns about the high potassium content of U.W. solution, which could stimulate the development of a calcium-related contracture with a consequent higher perfusion resistance caused by the contraction of the glomerular capillaries and impairment of the endothelium (13, 14) .
The problem of calcium overload is a hallmark of tissue injury after ischemia and reperfusion. The U.W. solution does not contain any component specifically designed to limit calcium overload and the low concentration of sodium ions inherent in its intracellular formulation is expected to promote the accumulation of calcium (15) . On the contrary, the formulation of Celsior has been studied to address this issue through its extracellular ionic formulation supplemented with magnesium.
Celsior has been used clinically in cardiac and lung preservation (7, 8) , but there have been only experimental approaches for use in the kidney (5, 16) . In a previous study, we demonstrated that Celsior has the same efficacy as that of U.W in cold storage of pig autotransplanted kidneys at 24 and 32 hr (16) .
In the present study, we evaluated the immediate clinical outcome and the 2-year follow-up of transplant recipients receiving allografts stored with either U.W. or Celsior preservation solution. The groups were comparable with regard to donor and recipient characteristics. The mean ischemia time was relatively short (16.5 for the Celsior group and 16.7 for the U.W. group) but we did not find any advantage of either solution in subgroups of the cases preserved for longer times.
This study shows the equivalence of Celsior compared to U.W. with respect to DGF and the other immediate functional parameters analyzed. There was a similar return of normal renal function (serum creatinine) and the postoperative dialysis rates were comparable (1.0 for Celsior group vs. 1.9 for U.W. group) and DGF values (31.3% for Celsior group vs. 33.9% for U.W. group). Moreover, there was no significant difference in graft survival rates between the Celsior and the U.W. groups after a 2-year follow-up, although some authors have reported that preservation solutions have only an immediate effect and do not affect long-term outcome (9) .
In conclusion, the analysis of the data obtained in our multicenter trial shows that Celsior is safe for kidney preservation. In another article (17), we reported our preliminary data that suggest that Celsior has the same effectiveness as that of U.W. in the cold storage of liver destined for transplantation. Therefore, the promising results in kidney and liver transplantation (17) using this preservation solution support the use of Celsior in multiple organ harvesting as a universal cold storage solution for intra-abdominal organs as well as for intrathoracic organs.
